Novartis: Kidney Diseases trials

The registry lists 13 Kidney Diseases studies with Novartis as lead sponsor. 3 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 3Phase 3 6Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruitingNCT07498335Phase 3
• Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.RecruitingNCT06858319Phase 3
• Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective StudyNot yet recruitingNCT06851845
• Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA NephropathyCompletedNCT05834738Phase 2Results posted
• Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.CompletedNCT03131479Phase 2Results posted
• A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes MellitusCompletedNCT00660309Phase 4Results posted
• Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant RecipientsCompletedNCT00284934Phase 3Results posted
• A Study of Zigakibart in Adults With IgA NephropathyActive, not recruitingNCT05852938Phase 3
• Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Phase 3
• PK of Serelaxin in Severe Renal Impairment and ESRDCompletedNCT01875523Phase 1
• Human Urine Sample Collection for Alport Nephropathy Biomarker StudiesTerminatedNCT01602835
• VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term HemodialysisCompletedNCT00171080Phase 3
• Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and ProteinuriaCompletedNCT00097955Phase 2